Ajay Kumar is an accomplished professional with experience in various Life science organizations including Biotech/Pharma, CROs, and Large Chemical conglomerates. Over a period of many years he has managed multiple projects from Drug Discovery to Early and mid-stage clinical trials. Some of the major projects include Paclitaxel “Taxol” and its analogs. He has also managed other INDs, aNDAs and CTA/CTX for iv and oral drugs. The different stages of projects and programs managed have varied from early discovery all the way to late Phase II (proof of concept) clinical trials.

Ajay also has the finance and business management education and training for creating and managing budgets, cost control, business plans, corporate finance, and corporate structure. Over the past few years, he has been successful in the areas of negotiation, in/out-licensing and contracting with the ability to package the license asset in a way to attract investors, but making sure that the scientific and medicinal goals are met or exceeded in those assets. Highly experienced in financial valuations (intrinsic or extrinsic) of various projects or firms using current financial tools, his valuations have been key in creating business plans for out-licensing or looking at value for in-licensing. Ajay has extensive experience in Mergers and Acquisitions and was the lead executive in the sale of one of his companies to a German holding corp. In addition, in the last 6 years Ajay has managed over 100 Due-Diligence efforts of varying complexity where teams have been assembled with scientific/technical, market analysis, Intellectual property and business/corporate/legal members.

Ajay has a PhD in Life Sciences and an MBA in finance from Rutgers University.